<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(34)</volume><submitter>Sun R</submitter><pubmed_abstract>Regulatory T (T&lt;sub>reg&lt;/sub>) cells and cancer-associated fibroblasts (CAFs) jointly promote tumor immune tolerance and tumorigenesis. The molecular apparatus that drives T&lt;sub>reg&lt;/sub> cell and CAF coordination in the tumor microenvironment (TME) remains elusive. Interleukin 33 (IL-33) has been shown to enhance fibrosis and IL1RL1&lt;sup>+&lt;/sup> T&lt;sub>reg&lt;/sub> cell accumulation during tumorigenesis and tissue repair. We demonstrated that IL1RL1 signaling in T&lt;sub>reg&lt;/sub> cells greatly dampened the antitumor activity of both IL-33 and PD-1 blockade. Whole tumor single-cell RNA sequencing (scRNA-seq) analysis and blockade experiments revealed that the amphiregulin (AREG)-epidermal growth factor receptor (EGFR) axis mediated cross-talk between IL1RL1&lt;sup>+&lt;/sup> T&lt;sub>reg&lt;/sub> cells and C</pubmed_abstract><journal>Science advances</journal><pagination>eadd7399</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10446484</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Amphiregulin couples IL1RL1&lt;sup>+&lt;/sup> regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity.</pubmed_title><pmcid>PMC10446484</pmcid><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Chen K</pubmed_authors><pubmed_authors>Lu X</pubmed_authors><pubmed_authors>Sun R</pubmed_authors><pubmed_authors>Chen L</pubmed_authors><pubmed_authors>Ni A</pubmed_authors><pubmed_authors>Gao DS</pubmed_authors><pubmed_authors>Zhao H</pubmed_authors><pubmed_authors>Lu B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Amphiregulin couples IL1RL1&lt;sup>+&lt;/sup> regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity.</name><description>Regulatory T (T&lt;sub>reg&lt;/sub>) cells and cancer-associated fibroblasts (CAFs) jointly promote tumor immune tolerance and tumorigenesis. The molecular apparatus that drives T&lt;sub>reg&lt;/sub> cell and CAF coordination in the tumor microenvironment (TME) remains elusive. Interleukin 33 (IL-33) has been shown to enhance fibrosis and IL1RL1&lt;sup>+&lt;/sup> T&lt;sub>reg&lt;/sub> cell accumulation during tumorigenesis and tissue repair. We demonstrated that IL1RL1 signaling in T&lt;sub>reg&lt;/sub> cells greatly dampened the antitumor activity of both IL-33 and PD-1 blockade. Whole tumor single-cell RNA sequencing (scRNA-seq) analysis and blockade experiments revealed that the amphiregulin (AREG)-epidermal growth factor receptor (EGFR) axis mediated cross-talk between IL1RL1&lt;sup>+&lt;/sup> T&lt;sub>reg&lt;/sub> cells and C</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Aug</publication><modification>2025-04-26T23:29:40.35Z</modification><creation>2025-04-06T17:35:47.147Z</creation></dates><accession>S-EPMC10446484</accession><cross_references><pubmed>37611111</pubmed><doi>10.1126/sciadv.add7399</doi></cross_references></HashMap>